David Global
21 Dec 2017
New Seeking Alpha article today another great article on Chi-Med posted today on Seeking Alpha2976233daa15453b007ec873b604b04&uprof=45&dr=1" target="blank" rel="nofollow">[link]
David Global
20 Dec 2017
Re: Seeking Alpha mention today "Strong science and solid management will be rewarded in good times and bad".....And that is exactly what we have in Chi-Med, striong science, a brilliant and solid management team and perfect execution of an excellent strategy....IMO!!
David Global
20 Dec 2017
Seeking Alpha mention today "Jonathan Faison Positions For 2018: Faster FDA Approval, Emerging Sector In China Bode Well For Biotech Next Year"[link] guys were very enthisiastic a year ago about Chi-Med and like me, that enthusiasm continues...I continue to buy
David Global
20 Dec 2017
Re: Bought more Sharp, I can only assume Mark Slater is adjusting his portfolio again due to the usual problem, he ends up exceeding 10% of the value of his Growth Fun
Sharpedge7
20 Dec 2017
Re: Bought more Hi David - do you have any idea who is selling at the mo as usually when volumes are high (for this stock) the price responds + - but hasn't in last day or so...
David Global
20 Dec 2017
Re: Bought more My xmas present to myself this morning was more HCM shares.....aiming to get my holding back up to 10,000 shares where it was 8 years ag
David Global
20 Dec 2017
Re: Bought more My xmas present to myself this morning was more HCM shares.....aiming to get my holding bacvk up to 10,000 shares where it was 8 years ag
Ramptastic
19 Dec 2017
Re: Bought more Couldn't resist re-buying the stock I sold @ £50 when the price dropped to £45.HCM hasn't been my most successful investment ever - but its getting close!Have a good Christmas everyone.Jim
David Global
19 Dec 2017
Re: Bought more I've just bought more again, as I do regularly and have done for the past 10 years.......there will be another large rise in the share price next year at the time of the results, and the approval by the CFDA of Fruquintinib.NASDAQ reacts very positively to material news and we have a lot to come during 2018. As the Evening Standard recently said, this will be at least a $20bn mcap company within the next few years, eg. five times its current valueI continue to buy
Sharpedge7
18 Dec 2017
Bought more Bought a few more today - had last bought at £45. Think might kick on again - we shall see.
David Global
18 Dec 2017
Re: Need a progress report CFDA approval for Frquintinib is due any time, especially as this will have been given a priority review for unmet medical needs, similar to the U.S. FDA's process. Could be approved within 6 - 8 months so that is any time now until Feb 18, may push out further but unlikelyLoads of other pipeline news due, the pipeline is growing and growing, now with the 3rd waveI continue to buy
sporty investor
13 Dec 2017
Need a progress report Share price in reverse gear. Hope Santa can provide an encouraging progress report for the sp to move forward.DG, are we expecting any news before the year end, about Chinese approval to our first drug?
David Global
04 Dec 2017
Re: Revised valuation? hi Bernie, thanks for your great insights, and I understand your point entirely about the P/S aspect. You point out the low debt, which is ceratinly something unusual in the developing Biotech space. It would be good if we do not have any more placings, although the market seems to have liked it, so I guess the view is the Company deploys its capital very well.
David Global
04 Dec 2017
New Deck I missed that this great new deck was posted at the end of Oct[link]
Boring Bernie
25 Nov 2017
Re: Revised valuation? I'd agree that £250 a share in 2026 is achievable.Mind you, by 2026, Chimed will (hopefully ) be a reasonably mature company, with a history of growing sales and, more importantly profits, so I'd disagree that valuing us on a forecast P/S ratio would be any use. Companies tend to be valued on P/S ratios when their profits are small ( or zero ), but are expected to grow as a result of increasing sales.2026, I think we'll be valued almost solely on our profits, and how they're growing.Given we have little no debt, our EV is the same as our market cap, so there seems little point in quoting EV/EBITDA ratios, by definition, they're going to be pretty much identical to the P/E ratio.Which leaves us with the P/E ratio that David's thrown up. For low to medium growth companies, a P/E of ~80 would be ridiculous, but if a company is growing or is expected to be growing it's profits at ( say ) 50% a year, then that'd give a PEG ratio of 1.6, which wouldn't be cheap, but would be justifiableIf profits were only growing at 25% per annum, then that'd give a PEG ratio of >3, which would, for me at least, be a pretty strong sell signal.It's all very theoretical anyway, because it's almost impossible to estimate what profits will be in nine years time. but, to stick with David's £250 per share in nine years, that'd mean we'd grow the sp by just under five times, which sounds fantastic, and it is, but it's actually "only" equivalent to an annual growth rate of 19%. I bought my first batch of shares in July 2012 at something like 390p ( probably at much the same time that David sold up first time round ) which are now worth 5200p, which is equivalent to an annual rate of ~40%, so, while a hoped for growth rate going forward of ~20% is very nice, it's got less margin of error if things don't go quite as hoped for, or take a bit longer.Mind you, I wish I hadn't sold a few at £40 so what on earth do I know !
